Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
Adenine
/ analogs & derivatives
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Disease Progression
Disease-Free Survival
Drug Administration Schedule
Female
Humans
Kaplan-Meier Estimate
Leukemia, Lymphocytic, Chronic, B-Cell
/ drug therapy
Male
Middle Aged
Neoplasm, Residual
Piperidines
Pyrazoles
/ administration & dosage
Pyrimidines
/ administration & dosage
Remission Induction
Rituximab
/ administration & dosage
Treatment Outcome
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
07 03 2019
07 03 2019
Historique:
received:
10
10
2018
accepted:
26
11
2018
pmc-release:
07
03
2020
pubmed:
12
12
2018
medline:
13
11
2019
entrez:
12
12
2018
Statut:
ppublish
Résumé
Ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, is an effective therapy for patients with chronic lymphocytic leukemia (CLL). To determine whether rituximab provides added benefit to ibrutinib, we conducted a randomized single-center trial of ibrutinib vs ibrutinib plus rituximab. Patients with CLL requiring therapy were randomized to receive 28-day cycles of once-daily ibrutinib 420 mg, either as a single agent (n = 104), or together with rituximab (375 mg/m
Identifiants
pubmed: 30530801
pii: S0006-4971(20)42720-X
doi: 10.1182/blood-2018-10-879429
pmc: PMC6405333
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Piperidines
0
Pyrazoles
0
Pyrimidines
0
ibrutinib
1X70OSD4VX
Rituximab
4F4X42SYQ6
Adenine
JAC85A2161
Banques de données
ClinicalTrials.gov
['NCT02007044']
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1011-1019Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 by The American Society of Hematology.
Références
Nat Rev Cancer. 2018 Mar;18(3):148-167
pubmed: 29348577
Blood. 2011 May 19;117(20):5463-72
pubmed: 21385850
Blood. 2018 Apr 26;131(17):1910-1919
pubmed: 29437592
Blood. 2010 Jun 3;115(22):4393-402
pubmed: 20194898
Blood. 2018 Oct 11;132(15):1568-1572
pubmed: 30111609
Blood. 2008 Jun 15;111(12):5446-56
pubmed: 18216293
Blood. 2012 Mar 15;119(11):2590-4
pubmed: 22279054
Blood. 2012 Feb 2;119(5):1182-9
pubmed: 22180443
J Exp Med. 2003 Nov 17;198(10):1539-50
pubmed: 14610042
N Engl J Med. 2014 Mar 13;370(11):997-1007
pubmed: 24450857
N Engl J Med. 2014 Mar 20;370(12):1101-10
pubmed: 24401022
Blood. 2015 Apr 16;125(16):2497-506
pubmed: 25700432
Leuk Lymphoma. 2013 Nov;54(11):2385-91
pubmed: 23425038
Trials. 2017 Aug 22;18(1):387
pubmed: 28830517
Lancet. 2015 May 9;385(9980):1873-83
pubmed: 25882396
J Clin Oncol. 2012 Sep 10;30(26):3209-16
pubmed: 22869884
Blood. 2015 Nov 5;126(19):2213-9
pubmed: 26337493
Lancet. 2010 Oct 2;376(9747):1164-74
pubmed: 20888994
N Engl J Med. 2016 Jan 28;374(4):311-22
pubmed: 26639348
N Engl J Med. 2018 Mar 22;378(12):1107-1120
pubmed: 29562156
Lancet Oncol. 2016 Feb;17(2):200-211
pubmed: 26655421
Lancet Oncol. 2014 Sep;15(10):1090-9
pubmed: 25150798
Leukemia. 2007 May;21(5):956-64
pubmed: 17361231
N Engl J Med. 2015 Dec 17;373(25):2425-37
pubmed: 26639149
N Engl J Med. 2013 Jul 4;369(1):32-42
pubmed: 23782158
Nat Rev Clin Oncol. 2018 Aug;15(8):510-527
pubmed: 29777163
Am J Hematol. 2018 Nov;93(11):1402-1410
pubmed: 30129285
Immunity. 2007 Jan;26(1):93-104
pubmed: 17239630
J Immunol. 2017 Feb 15;198(4):1740-1747
pubmed: 28077600